Home > News & Updates

Aptamer Group October 2018

19th October 2018.
This month data on our new improved delivery standard, webinar with Pall ForteBio, and interesting applications in targeted treatment and environmental detection of small molecules.

Following on from a successful Series A investment and lots of new data ongoing for multiple applications in the commercial and academic space the Aptamer Group would like to […]

Fully Optimised Aptamers

Introducing OptimersTM
3rd October 2018
 
Proprietary process with validated improvement in delivery and performance

OptimersTM in 12 weeks
Aptamer Group is pleased to announce availability of  OptimersTM – the new standard for our custom development services.

Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the […]

Upcoming October Events

24th September 2018
Aptamer Group has had a busy summer growing and preparing to launch a disruptive aptamer approach that will create better opportunities and results for our collaborators.  We will be available and sharing information at the following events in October:
1 October 2018-Milner Therapeutics Symposium, Cambridge UK
As a Milner Therapeutics Institute Alliance Partner we will […]

Aptamer Stability

29th August 2018
At Aptamer Group, every custom aptamer project begins with a feasibility study. The target and assay matrix are tested for compatibility and stability with the aptamer library, under a variety of conditions. At this early stage it is important to understand the optimal strategy for the selection, address any potential issues and […]

Portable Aptamer Based Sensor for Toxin Detection

9th August 2018 
Aptamers continue to demonstrate advantages in platforms and applications which require specific detection of small molecule targets.
There has been a growth in the use of point of care devices across a range of applications and assay types due to a need for rapid and reliable analysis (Vashist 2017). Aptamers are perfectly suited for […]

Aptamer-based Lab on chip for the rapid detection of food-borne pathogens

1st August 2018
Scientists from the Technical University of Denmark, led by  Krishna  Kant have published a new review in Biotechnology Advances including  aptamer-based approaches  for the rapid detection of food-borne pathogens.
Food borne diseases, caused by the consumption of foods contaminated with pathogens or their toxins, are one of the major burdens to public health, causing […]

Aptamer Group Secures $2.2m Series A Investment

Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.

Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market […]

Aptamers used to enhance a commercially available biosensor for hormone monitoring

22nd June 2018
Introduction:

Changes in hormone levels can be key indicators to a variety of issues, examples include testosterone levels in general health and well being(1) and diagnosing Cushing’s disease involving the steroid cortisol (2). While these small molecules and others are well documented and their role in health and disease is becoming better understood, researchers […]

Congratulations to Dr Mateja Vidic

1st June 2018

We are very pleased to announce that Mateja Vidic has completed and been awarded her PhD for the Development of DNA Aptamers Specific for Non-Small Cell Lung Cancer by the University of Ljubljana, Slovenija. Her experience in aptamer selection and application is a valuable asset to our lab and we are very proud […]

New licenses for Aptamer Group aptamers for innovative diagnostic development

Exclusive licence deals to follow successful custom aptamer selection
25th May 2018
Aptamer Group is pleased to announce that we are now working on multiple projects where long term licencing deals have been negotiated with customers based in the UK and USA. This is an important ongoing commercial strategy for us and we look forward to developing […]

Connect with us